Ginkgo Bioworks unit Zymergen filed for Chapter 11 bankruptcy in Delaware. Neither Ginkgo nor other subsidiaries are filing for bankruptcy protection.
- Ginkgo ended the second quarter of 2023 with $1.1 billion of cash and cash equivalents
- Ginkgo entered into an asset purchase agreement with Zymergen as the stalking horse bidder to acquire exclusive rights to substantially all of Zymergen’s intellectual property assets and certain other assets
- Ginkgo’s bid includes a $5 million cash component and assumption of up to $77 million of potential future liabilities, including a lease
To view the source of this information, click
To contact the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.